Literature DB >> 12566594

Rates of cognitive decline in Alzheimer's disease and dementia with Lewy bodies.

Edward Helmes1, John V Bowler, Harold Merskey, David G Munoz, Vladimir C I Hachinski.   

Abstract

Increased interest in types of dementia has developed as more cases are identified in aging populations. Here we compare the rates of cognitive decline over time in three groups with dementia from the University of Western Ontario Dementia Study: Alzheimer's disease (AD), dementia with Lewy bodies and a group with both AD and Lewy bodies. All diagnoses were verified by autopsy using standard diagnostic methods. Cognitive impairment was measured with the Extended Scale for Dementia (ESD). Members of each group with dementia were age and sex matched with individuals without dementia as controls. The 15 cases of AD, 7 cases with Lewy bodies and 8 cases with both conditions were all free of significant vascular disease. Linear regression was used to determine the rate of changes in ESD scores over time in months. All three control groups showed no change in cognitive status over time. As expected, all groups with dementia showed progressive cognitive impairment. Analysis of the slope parameter showed that all groups deteriorated at the same rate of approximately 2 ESD points per month. Quadratic models fit better than simple linear models in all groups. Results suggest that the final rate of cognitive decline in dementia may not necessarily reflect the underlying cause. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 12566594     DOI: 10.1159/000067969

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  9 in total

1.  Visual Perceptual Organization Ability in Autopsy-Verified Dementia with Lewy Bodies and Alzheimer's Disease.

Authors:  Micaela Mitolo; Joanne M Hamilton; Kelly M Landy; Lawrence A Hansen; Douglas Galasko; Francesca Pazzaglia; David P Salmon
Journal:  J Int Neuropsychol Soc       Date:  2016-05-25       Impact factor: 2.892

2.  Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies.

Authors:  D J Burn; E N Rowan; L M Allan; S Molloy; J T O'Brien; I G McKeith
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05       Impact factor: 10.154

3.  The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease.

Authors:  Micaela Mitolo; David P Salmon; Simona Gardini; Douglas Galasko; Enzo Grossi; Paolo Caffarra
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

4.  Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies.

Authors:  Joanne M Hamilton; David P Salmon; Douglas Galasko; Rema Raman; Jenn Emond; Lawrence A Hansen; Eliezer Masliah; Leon J Thal
Journal:  Neuropsychology       Date:  2008-11       Impact factor: 3.295

5.  Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.

Authors:  J A Schneider; Z Arvanitakis; L Yu; P A Boyle; S E Leurgans; D A Bennett
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

6.  Are hallucinations and extrapyramidal signs associated with a steeper cognitive decline in degenerative dementia patients?

Authors:  E Capitani; A Francescani; H Spinnler
Journal:  Neurol Sci       Date:  2007-10-31       Impact factor: 3.307

Review 7.  Dementia with Lewy bodies.

Authors:  Tanis J Ferman; Bradley F Boeve
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

8.  A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer's disease.

Authors:  Monica H Breitve; Luiza J Chwiszczuk; Minna J Hynninen; Arvid Rongve; Kolbjørn Brønnick; Carmen Janvin; Dag Aarsland
Journal:  Alzheimers Res Ther       Date:  2014-09-16       Impact factor: 6.982

9.  The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia.

Authors:  Kajsa Stubendorff; Dag Aarsland; Lennart Minthon; Elisabet Londos
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.